Pfizer (PFE) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Pfizer Revenue Highlights

Latest Revenue (Y)

$58.50B

Latest Revenue (Q)

$17.70B

Main Segment (Y)

Biopharma Segment

Main Geography (Y)

UNITED STATES

Pfizer Revenue by Period

Pfizer Revenue by Year

Date	Revenue	Change
2023-12-31	$58.50B	-41.70%
2022-12-31	$100.33B	23.43%
2021-12-31	$81.29B	93.97%
2020-12-31	$41.91B	-19.02%
2019-12-31	$51.75B	-3.54%
2018-12-31	$53.65B	2.10%
2017-12-31	$52.55B	-0.53%
2016-12-31	$52.82B	8.13%
2015-12-31	$48.85B	-1.52%
2014-12-31	$49.60B	-3.84%
2013-12-31	$51.58B	-12.55%
2012-12-31	$58.99B	-12.52%
2011-12-31	$67.42B	-0.57%
2010-12-31	$67.81B	35.59%
2009-12-31	$50.01B	3.55%
2008-12-31	$48.30B	-0.25%
2007-12-31	$48.42B	0.10%
2006-12-31	$48.37B	-5.71%
2005-12-31	$51.30B	-2.32%
2004-12-31	$52.52B	16.22%
2003-12-31	$45.19B	39.59%
2002-12-31	$32.37B	0.35%
2001-12-31	$32.26B	9.08%
2000-12-31	$29.57B	82.51%
1999-12-31	$16.20B	19.64%
1998-12-31	$13.54B	8.32%
1997-12-31	$12.50B	10.60%
1996-12-31	$11.31B	12.82%
1995-12-31	$10.02B	21.01%
1994-12-31	$8.28B	10.75%
1993-12-31	$7.48B	-

Pfizer generated $58.50B in revenue during NA 2023, up -41.70% compared to the previous quarter, and up 109.04% compared to the same period a year ago.

Pfizer Revenue by Quarter

Date	Revenue	Change
2024-09-30	$17.70B	33.27%
2024-06-30	$13.28B	-10.73%
2024-03-31	$14.88B	4.42%
2023-12-31	$14.25B	7.69%
2023-10-01	$13.23B	3.91%
2023-07-02	$12.73B	-30.35%
2023-04-02	$18.28B	-24.73%
2022-12-31	$24.29B	7.30%
2022-10-02	$22.64B	-18.40%
2022-07-03	$27.74B	8.11%
2022-04-03	$25.66B	7.65%
2021-12-31	$23.84B	-1.06%
2021-10-03	$24.09B	26.96%
2021-07-04	$18.98B	30.14%
2021-04-04	$14.58B	24.80%
2020-12-31	$11.68B	-3.68%
2020-09-27	$12.13B	2.80%
2020-06-28	$11.80B	-1.89%
2020-03-29	$12.03B	-5.20%
2019-12-31	$12.69B	0.06%
2019-09-29	$12.68B	-4.40%
2019-06-30	$13.26B	1.11%
2019-03-31	$13.12B	-6.14%
2018-12-31	$13.98B	5.10%
2018-09-30	$13.30B	-1.25%
2018-07-01	$13.47B	4.34%
2018-04-01	$12.91B	-5.82%
2017-12-31	$13.70B	4.06%
2017-10-01	$13.17B	2.11%
2017-07-02	$12.90B	0.92%
2017-04-02	$12.78B	-6.22%
2016-12-31	$13.63B	4.46%
2016-10-02	$13.04B	-0.78%
2016-07-03	$13.15B	1.09%
2016-04-03	$13.01B	-7.42%
2015-12-31	$14.05B	16.22%
2015-09-27	$12.09B	1.97%
2015-06-28	$11.85B	9.10%
2015-03-29	$10.86B	-17.18%
2014-12-31	$13.12B	6.12%
2014-09-28	$12.36B	-3.23%
2014-06-29	$12.77B	12.51%
2014-03-30	$11.35B	-16.26%
2013-12-31	$13.56B	7.24%
2013-09-29	$12.64B	-2.54%
2013-06-30	$12.97B	-3.90%
2013-03-31	$13.50B	-10.41%
2012-12-31	$15.07B	7.81%
2012-09-30	$13.98B	0.06%
2012-07-01	$13.97B	0.89%
2012-04-01	$13.85B	-17.32%
2011-12-31	$16.75B	0.82%
2011-10-02	$16.61B	0.75%
2011-07-03	$16.48B	2.88%
2011-04-03	$16.02B	-8.75%
2010-12-31	$17.56B	9.79%
2010-10-03	$15.99B	-6.64%
2010-07-04	$17.13B	3.35%
2010-04-04	$16.58B	0.24%
2009-12-31	$16.54B	42.30%
2009-09-27	$11.62B	5.80%
2009-06-28	$10.98B	1.08%
2009-03-29	$10.87B	-11.98%
2008-12-31	$12.35B	3.12%
2008-09-28	$11.97B	-1.29%
2008-06-29	$12.13B	2.37%
2008-03-30	$11.85B	-7.94%
2007-12-31	$12.87B	-

Pfizer generated $17.70B in revenue during Q3 2024, up 33.27% compared to the previous quarter, and up 139.01% compared to the same period a year ago.

Pfizer Revenue Breakdown

Pfizer Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Biopharma Segment	$57.19B	$98.99B	$6.50B	-	-
Comirnaty	-	$3.10B	-	-	-
Total Alliance Biopharmaceuticals	-	$8.54B	$7.65B	$5.42B	-
Total Sterile Injectable Pharmaceuticals	-	-	$5.75B	$5.32B	-
Total Biosimilars	-	-	$2.34B	$1.53B	-
Consumer Healthcare	-	-	-	-	$2.10B

Pfizer's latest annual revenue breakdown by segment (product or service), as of Dec 23: Biopharma Segment (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Oct 23	Jul 23	Apr 23	Dec 22	Oct 22	Jul 22	Apr 22	Dec 21	Oct 21	Jul 21	Apr 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Biopharma Segment	$17.39B	$2.07B	$2.17B	$13.87B	$12.93B	$1.72B	$1.25B	$1.61B	$1.81B	-	-	-	-	-	-	-	-	-	-	-
Comirnaty	-	-	-	-	$140.00M	$300.00M	$1.70B	$600.00M	$68.00M	$800.00M	-	-	-	-	-	-	-	-	-	-
Total Alliance Biopharmaceuticals	-	-	-	-	-	$1.97B	$1.69B	$2.32B	$2.31B	$1.93B	$2.07B	$1.88B	$1.77B	-	-	-	-	-	-	-
Total Sterile Injectable Pharmaceuticals	-	-	-	-	-	-	-	-	-	$1.29B	$1.33B	$1.44B	$1.44B	$1.38B	$1.48B	-	-	-	-	-
Total Biosimilars	-	-	-	-	-	-	-	-	-	$580.00M	$605.00M	$680.00M	$575.00M	$559.00M	$530.00M	-	-	-	-	-
Upjohn Segment	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$76.00M	$79.00M	$78.00M	$77.00M	$74.00M
Biopharma, Upjohn And Consumer Healthcare Segments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$12.13B	$11.80B	$12.03B	$1.33B	$12.68B
Consumer Healthcare	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$377.00M

Pfizer's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Biopharma Segment (100.00%).

Pfizer Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
UNITED STATES	$27.09B	$42.47B	$29.75B	$21.71B	$23.85B
Developed Europe	$11.65B	$21.98B	-	-	-
Developed Rest Of World	$7.76B	$15.78B	-	-	-
Emerging Markets	$12.00B	$20.10B	-	-	-

Pfizer's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (46.31%), Emerging Markets (20.51%), Developed Europe (19.92%), and Developed Rest Of World (13.27%).

Quarterly Revenue by Country

Country	Sep 24	Jun 24	Mar 24	Dec 23	Oct 23	Jul 23	Apr 23	Oct 22	Jul 22	Apr 22	Dec 21	Oct 21	Jul 21	Apr 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Emerging Markets	$2.23B	$2.23B	$2.17B	$2.31B	$2.37B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
UNITED STATES	$12.06B	$7.89B	$9.51B	$4.59B	$7.80B	$6.18B	$8.51B	$13.85B	$11.22B	$8.92B	$7.48B	$7.08B	$7.59B	$7.60B	$4.94B	$5.72B	$5.40B	$5.65B	$5.49B	$5.85B
Developed Rest Of World	$3.41B	$3.16B	$3.20B	$2.91B	$1.07B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Developed Europe	-	-	-	$4.43B	$1.98B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Pfizer's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (68.15%), Developed Rest Of World (19.27%), and Emerging Markets (12.57%).

Pfizer Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
JNJ	Johnson & Johnson	$85.15B	$22.47B
MRK	Merck	$60.12B	$16.66B
PFE	Pfizer	$58.50B	$17.70B
ABBV	AbbVie	$54.32B	$14.46B
BMY	Bristol-Myers Squibb Company	$45.01B	$11.89B
LLY	Eli Lilly and Company	$34.12B	$11.44B
AMGN	Amgen	$28.19B	$8.50B
GILD	Gilead Sciences	$27.12B	$7.55B

PFE Revenue FAQ

What is Pfizer’s yearly revenue?

Pfizer's yearly revenue for 2023 was $58.5B, representing a decrease of -41.70% compared to 2022. The company's yearly revenue for 2022 was $100.33B, representing an increase of 23.43% compared to 2021. PFE's yearly revenue for 2021 was $81.29B, representing an increase of 93.97% compared to 2020.

What is Pfizer’s quarterly revenue?

Pfizer's quarterly revenue for Q3 2024 was $17.7B, a 33.27% increase from the previous quarter (Q2 2024), and a 33.78% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $13.28B, a -10.73% decrease from the previous quarter (Q1 2024), and a 4.31% increase year-over-year (Q2 2023). PFE's quarterly revenue for Q1 2024 was $14.88B, a 4.42% increase from the previous quarter (Q4 2023), and a -18.61% decrease year-over-year (Q1 2023).

What is Pfizer’s revenue growth rate?

Pfizer's revenue growth rate for the last 3 years (2021-2023) was -28.04%, and for the last 5 years (2019-2023) was 13.04%.

What are Pfizer’s revenue streams?

Pfizer's revenue streams in c 23 are Biopharma Segment

What is Pfizer’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Pfizer was Biopharma Segment. This segment made a revenue of $57.19B, representing 100.00% of the company's total revenue.